These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 18091431)

  • 1. Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors.
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2007 Dec; 9(12):819-25. PubMed ID: 18091431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs).
    Matchar DB; Thakur ME; Grossman I; McCrory DC; Orlando LA; Steffens DC; Goldstein DB; Cline KE; Gray RN
    Evid Rep Technol Assess (Full Rep); 2007 Jan; (146):1-77. PubMed ID: 17764209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors.
    Thakur M; Grossman I; McCrory DC; Orlando LA; Steffens DC; Cline KE; Gray RN; Farmer J; DeJesus G; O'Brien C; Samsa G; Goldstein DB; Matchar DB
    Genet Med; 2007 Dec; 9(12):826-35. PubMed ID: 18091432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2014 Apr; 16(4):338-46. PubMed ID: 24071797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group.
    Teutsch SM; Bradley LA; Palomaki GE; Haddow JE; Piper M; Calonge N; Dotson WD; Douglas MP; Berg AO;
    Genet Med; 2009 Jan; 11(1):3-14. PubMed ID: 18813139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2009 Jan; 11(1):15-20. PubMed ID: 19125128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations from the EGAPP Working Group: does genomic profiling to assess type 2 diabetes risk improve health outcomes?
    ;
    Genet Med; 2013 Aug; 15(8):612-7. PubMed ID: 23492873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*
    Genet Med; 2016 Aug; 18(8):770-9. PubMed ID: 26681310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations from the EGAPP Working Group: genomic profiling to assess cardiovascular risk to improve cardiovascular health.
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2010 Dec; 12(12):839-43. PubMed ID: 21042222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neither cytochrome P450 family genes nor neuroendocrine factors could independently predict the SSRIs treatment in the Chinese Han population.
    Zhang X; Yu T; Li X; Li X; Huang X; Li X; He L; He G; Sun X
    Pharmacopsychiatry; 2014 Mar; 47(2):60-6. PubMed ID: 24488700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP450 genotype and aggressive behavior on selective serotonin reuptake inhibitors.
    Ekhart C; Matic M; Kant A; van Puijenbroek E; Schaik RV
    Pharmacogenomics; 2017 May; 18(7):613-620. PubMed ID: 28470107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors.
    Probst-Schendzielorz K; Viviani R; Stingl JC
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1219-32. PubMed ID: 26028357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients.
    Smits KM; Smits LJ; Peeters FP; Schouten JS; Janssen RG; Smeets HJ; van Os J; Prins MH
    Psychiatr Genet; 2008 Aug; 18(4):184-90. PubMed ID: 18628680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2009 Jan; 11(1):66-73. PubMed ID: 19125125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The economics of selective serotonin reuptake inhibitors in depression: a critical review.
    Frank L; Revicki DA; Sorensen SV; Shih YC
    CNS Drugs; 2001 Jan; 15(1):59-83. PubMed ID: 11465013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic consequences of selective serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P-450 system.
    Ozminkowski RJ; Hylan TR; Melfi CA; Meneades LM; Crown WH; Croghan TW; Robinson RL
    Clin Ther; 1998; 20(4):780-96. PubMed ID: 9737837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.
    Edwards SJ; Hamilton V; Nherera L; Trevor N
    Health Technol Assess; 2013 Nov; 17(54):1-190. PubMed ID: 24284258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members.
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2011 Jan; 13(1):67-76. PubMed ID: 21150787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective serotonin reuptake inhibitor poisoning: An evidence-based consensus guideline for out-of-hospital management.
    Nelson LS; Erdman AR; Booze LL; Cobaugh DJ; Chyka PA; Woolf AD; Scharman EJ; Wax PM; Manoguerra AS; Christianson G; Caravati EM; Troutman WG
    Clin Toxicol (Phila); 2007 May; 45(4):315-32. PubMed ID: 17486478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.